CervoMed Inc. announced on July 28, 2025, positive 32-week data from the Extension phase of its Phase 2b RewinD-LB trial, demonstrating that oral neflamapimod continued to slow disease progression in patients with Dementia with Lewy Bodies (DLB). Patients treated with neflamapimod showed a 54% risk reduction in clinically significant worsening based on the Clinical Dementia Rating Sum of Boxes (CDR-SB) compared to control at Week 32 (p=0.0037).
This risk reduction further improved to 64% (p=0.0001) among patients with minimal evidence of Alzheimer’s Disease (AD) co-pathology (ptau181 < 2.2 pg/mL at screening). These results underscore neflamapimod’s potential to significantly impact clinical progression, a gold standard measure in dementia trials.
Additionally, at Week 32 of the Extension phase, patients treated with neflamapimod demonstrated a statistically significant reduction from baseline in plasma levels of glial fibrillary acidic protein (GFAP), a key plasma biomarker of neurodegeneration. CervoMed plans to meet with the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2025 to align on the design of a Phase 3 clinical trial.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.